Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions. In ...

making smoking cessation a critical part of treatment along with medications, oxygen therapy, and lifestyle changes Chronic obstructive pulmonary disease, commonly referred to as COPD, is a group ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

Using imaging and respiratory symptoms, researchers identified up to 15.4% of individuals without airflow obstruction as ...

The Hailie Smartinhaler device has also been cleared for use with inhalers from other manufacturers ... sells the device directly to patients with asthma and COPD under a 510(k) over-the-counter ...